CAR T Toxicity Differences Seen in Transplant-Ineligible LBCL
During a live event, Nathan M. Denlinger, DO, MS, discussed the PILOT and ALYCANTE trials of CAR T-cell therapy in transplant-ineligible B-cell lymphoma.
Related Articles
Phase 1b Data Suggest Paxalisib Combo May Suppress CTCs in Metastatic TNBC
A promising clinical trial shows that a combination of paxalisib, pembrolizumab, and chemotherapy significantly reduces circulating tumor cells in metastatic triple-negative breast cancer.
Lower-Risk MDS Treatment Paradigms and Considerations for Transfusion and Pharmacologic Therapies
An expert discusses how the treatment landscape for lower-risk MDS has evolved with multiple new options including luspatercept, imetelstat, and lenalidomide based on specific patient…
Exploring MRD Testing and Data in Myeloma to Guide Treatment Decisions
During a live event, Jeffrey V. Matous, MD, discussed bispecific antibody treatment efficacy and safety in advanced multiple myeloma.
Dr Liu on Lurbinectedin: A New Era in SCLC Maintenance
New research reveals that combining lurbinectedin with atezolizumab significantly improves survival rates for patients with extensive-stage small cell lung cancer.
New Colorectal Cancer Therapies: Hope on the Horizon
Anita Turk, MD, discusses what she is most excited about regarding immunotherapy in the realm of colorectal cancer treatment.
Evolving Treatment Paradigms in Lower-Risk MDS: Current Therapeutic Options and Mechanistic Approaches
A panelist explains how the distinct mechanisms of erythropoiesis-stimulating agents (ESAs), luspatercept, and imetelstat offer tailored treatment options for anemia in lower-risk ESAs, enabling clinicians…
PD-L1 and HRD Correlation Shows Prognostic Value in Ovarian Cancer
New research reveals PD-L1 expression enhances survival in advanced ovarian cancer, linking it to homologous recombination deficiency and treatment personalization.
Dr Spigel Covers the AIM-HIGH Trial in Early NSCLC
David Spigel, MD, discusses the pivotal findings from the AIM-HIGH trial in early-stage non-squamous NSCLC.
FDA Draft Guidance Illuminates MDS Drug Development Pathways
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.
Dr Klempner Highlights Practice-Changing Role of Durvalumab/FLOT in Gastric Cancer
Durvalumab enhances event-free survival in resectable gastric and gastroesophageal cancers, revolutionizing neoadjuvant therapy according to the MATTERHORN trial.